Reflections on market access for personalized medicine: recommendations for Europe.
about
Economic evaluations of personalized medicine: existing challenges and current developmentsPersonalized medicine in Europe: not yet personal enough?Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population.A Systematic Review of Health Economic Evaluations of Diagnostic Biomarkers.Was it worth it? Patients' perspectives on the perceived value of genomic-based individualized medicine.Economic Evaluation in Stratified Medicine: Methodological Issues and ChallengesImplementing personalized medicine with asymmetric information on prevalence rates.Perceptions and factors affecting pharmaceutical market access: results from a literature review and survey of stakeholders in different settingsENVIRONMENTAL SCAN ON PHARMACEUTICALS REQUIRING COMPANION DIAGNOSTICS.Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online.Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO).Understanding barriers to the introduction of precision medicines in non-small cell lung cancer: A qualitative interview protocol.The economic case for precision medicine.Toward health technology assessment of whole-genome sequencing diagnostic tests: challenges and solutions
P2860
Q26797183-A3481D7C-5C45-4A67-B5CD-FD1F9B0E33C7Q33577079-5E15B0AD-6F1D-4F09-A27A-7FFB1E11BD34Q35713241-8A4E3FEF-1856-4D8D-9C68-9DE4DA8536A7Q36541715-6586BC81-E3B0-4621-B792-B9B64B4CE30EQ36698414-F75992BD-2EB2-4C0D-97B5-BFEEDA3C1476Q36883280-E00FE30C-966A-4F2E-A740-CF45052C4322Q37188012-6DB6573D-7825-4D05-8441-6A2CAD76F550Q37293459-FD04F2C9-3BEC-412C-941C-F2B3B02478B0Q38783892-CE797B1A-3A8E-483C-81FE-D4FACC7B5F69Q42690907-2ED5A71E-C0C6-4A3F-8EEA-05560C2AFF90Q48873124-DBCC5076-F9E3-4526-9575-2D08C7B6B206Q55007332-1252D97C-ACEF-42DA-A57B-C999266588C9Q55217201-DE199808-260D-42CC-8877-6BE71B39FCDBQ57697360-6CBED150-C8D7-42E7-AEE4-76DF0E67A0CC
P2860
Reflections on market access for personalized medicine: recommendations for Europe.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Reflections on market access for personalized medicine: recommendations for Europe.
@en
type
label
Reflections on market access for personalized medicine: recommendations for Europe.
@en
prefLabel
Reflections on market access for personalized medicine: recommendations for Europe.
@en
P1433
P1476
Reflections on market access for personalized medicine: recommendations for Europe.
@en
P2093
Lieven Annemans
P356
10.1016/J.JVAL.2013.06.010
P433
P577
2013-09-01T00:00:00Z